Vol 97, No 8 (2025): Treatment issues

Cover Page

Full Issue

Editorial

Current status and prospects of using potassium-competitive acid blockers in gastroenterology

Maev I.V., Andreev D.N., Zaborovsky A.V., Fomenko A.K.

Abstract

Over the past decades, acid production in the stomach has been regulated mainly by proton pump inhibitors (PPIs). However, despite their widespread use and solid evidence base for efficacy, PPIs have pharmacokinetic and pharmacodynamic limitations, such as a slow onset of action, response variability (dependent on CYP2C19 polymorphisms), and the need for activation in an acidic environment. These restrictions underscore the need for innovative molecular approaches to inhibiting acid production, which led to the development of a fundamentally different mechanism of action – potassium-competitive acid blockers (P-CABs), first introduced into clinical practice in 2015. The mechanism of action of P-CABs is based on a reversible ionic interaction with hydrogen potassium adenosine triphosphatase (H+/K+ ATPase) in parietal cells of the stomach. Direct inhibition of the active enzyme enables more rapid and sustained control of gastric secretion, including nocturnal and postprandial acid production, making this class of drugs particularly relevant in the treatment of gastroesophageal reflux disease, peptic ulcers, and in the eradication of Helicobacter pylori. Recent meta-analyses demonstrate the clinical benefits of P-CABs over PPIs for these indications.

Terapevticheskii arkhiv. 2025;97(8):611-617
pages 611-617 views

Original articles

Impact of atrial functional mitral regurgitation on clinical outcomes in patients with HFpEF and atrial fibrillation during optimal drug therapy

Safarova A.F., Kobalava Z.D., Adam S.B., Timofeeva T.M.

Abstract

Aim. To evaluate the clinical and prognostic significance of atrial functional mitral regurgitation (AFMR) in patients with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) on the background of optimal drug therapy.

Materials and methods. The retrospective study included 150 patients (age 75.5 ± 9.9 years, 54% men) with HFpEF with AF and AFMR on the background of optimal drug therapy. Clinical and demographic characteristics (including the scale of assessment of the clinical condition), laboratory and instrumental diagnostic results, and drug therapy were evaluated. MR was assessed as minor, moderate, or severe using a multiparametric approach, including an assessment of the effective area of the regurgitation hole and the MR fraction. The effect of AFMR on rehospitalization for HF, combined endpoint (CE) was studied [cardiovascular death (CVD) and rehospitalization] during the follow-up period of 589 (217–1039) days.

Results. Eighty (53.3%) patients had moderate AFMR, and 23 (15.3%) had severe AFMR. These patients had lower SBP and DBP values (p = 0.014), and permanent AF was more common among them (p = 0.025) compared with patients with minor MR. Independent predictors of moderate/severe AFMR were the constant form of AF (OR 3.3 [1.4–8.0]; p = 0.007), end-systolic left ventricular distance (OR 3.0 [1.4–6.5]; p = 0.006), taking antiplatelet agents (OR 0.11 [0.02–0.70]; p = 0.020). The frequency of outcomes in the general group was 46.7% for CE, 34.0% for rehospitalization for HF, and 14.0% for CVD. The predictors of CE were moderate/severe FMR (HR 2.6 [1.4–4.9]; p = 0.002), scores on the scale of assessment of the clinical condition (HR 1.14 [1.04–1.25]; p = 0.003); severe FMR (HR 4.1 [1.7–10.2]; p = 0.002), moderate FMR (HR 2.7 [1.2–5.8]; p = 0.013), creatinine level (HR 0.990 [0.980–1,000]; p = 0.040).

Conclusion. Despite the limitations, the importance of AFMR as a factor influencing clinical outcomes in patients with HFpEF and AF has been demonstrated. The present study highlights the need for further investigation of this condition and the development of personalized patient management strategies.

Terapevticheskii arkhiv. 2025;97(8):618-626
pages 618-626 views

Clinical and morphological features and functional parameters in patients with gastroesophageal reflux disease and Barrett's esophagus

Trukhmanov A.S., Paraskevova A.V., Storonova O.A., Пономарев A.Б., Makushina A.A., Ivashkin V.T.

Abstract

Aim. To develop a treatment strategy based on the analysis of clinical manifestations and the results of morphofunctional diagnostics for patients with gastroesophageal reflux disease (GERD) aimed at preventing the development and progression of intestinal metaplasia (IM) of the esophageal epithelium.

Materials and methods. The study included 50 subjects diagnosed with GERD. After esophagogastroduodenoscopy with biopsy and subsequent morphological examination of the esophageal mucosa, two groups were formed: patients with GERD complicated by IM, also known as Barrett’s esophagus (n = 19), patients with GERD without IM (n = 31). All participants underwent high-resolution esophageal manometry and 24-hour impedance pH monitoring.

Results. The study found that in patients with GERD complicated by IM, complaints of intense heartburn and difficulty swallowing occurred more often than in patients with GERD without IM. According to manometry, the resting pressure of the lower esophageal sphincter in patients with GERD and IM (15.1 [1.3; 36.4] mmHg) was lower than in patients with GERD without IM (20.3 [5.5; 42.1] mmHg). This difference was statistically significant (p = 0.002). In patients with GERD and IM, esophageal motility is less effective; this was translated in a decrease in the distal contractile integral of the esophagus to 276.5 [0.2; 567.7] mmHg × s × cm, while in patients with GERD without IM, it was much higher: 942.5 [47.3; 3759.7] mmHg × s × cm. Difficulties in swallowing were associated with a reduced effectiveness of esophageal motility. In patients with GERD complicated by IM, more acid gastroesophageal refluxes were observed compared to patients without IM (72.5 [53.5; 91.5] vs 54.2 [29.9; 78.3]; p = 0.036). They also have a greater percentage of time with pH < 4.0 in the esophagus (14.5 [9.7; 19.3] vs 10.3 [5.6; 14.9]; p = 0.028) and higher DeMeester index values (35.4 [1.9; 114.5] vs 15.1 [0.2; 47.7]; p = 0.004).

Conclusion. GERD is a multifactorial disease with a primary impairment of the motor function of the upper gastrointestinal tract. The acidic reflux may affect the development of the intestinal type of epithelial metaplasia.

Terapevticheskii arkhiv. 2025;97(8):627-634
pages 627-634 views

Features of the phenotypic manifestations of GERD in its comorbidity with obesity

Maev I.V., Yurenev G.L., Mironova E.M.

Abstract

Aim. To optimize the algorithm of diagnosis and treatment of patients with gastroesophageal reflux disease (GERD) with comorbid obesity based on a comprehensive analysis of the clinical and functional characteristics of the disease.

Materials and methods. The study included 150 patients who underwent esophagogastroduodenoscopy, 24-hour pH-measurement or 24-hour pH-impedancometry of the esophagus. A stratification was carried out basing on the presence of typical GERD complaints and body mass index (BMI). Group 1 consisted of 30 patients with GERD and normal body weight; group 2 – 60 patients with GERD who were overweight or obese; group 3 – 30 patients without GERD, but overweight or obese; control group – 30 people with normal body weight without GERD, but with similar complaints due to functional disorders of the esophagus.

Results. When comparing esophageal pH-impedancometry data, it was found that the volume clearance time did not differ between the groups of patients with normal body weight and overweight, but in obese people reflux with pH > 7 was recorded more often and for a longer time. The duration of chemical clearance (DCC) was increased in both groups, however, with overweight (BMI > 25 kg/m2), DCC was shorter, and with obesity (BMI > 30 kg/m2), it was longer than in people with normal body weight. At the same time, as body weight increases, the frequency of mixed (gastric and duodenal) reflux also rises up.

Conclusion. A comprehensive analysis of the characteristics of refluxate allows us to assess the course of the disease in more details, make assumptions about a unique combination of aggression factors for each patient, determine the severity of damage to the mucous membrane of the esophagus and, thanks to this, optimize approaches to therapy.

Terapevticheskii arkhiv. 2025;97(8):635-641
pages 635-641 views

The high-dose dual therapy for eradication of Helicobacter pylori: efficacy and safety

Bakulina N.V., Ponomarenko V.A., Kerimova A.S., Thai Hien T., Shikhmagomedova A.S., Veliev A.M., Savilova I.V.

Abstract

Background. The article presents the results of a prospective open-label comparative interventional study of the efficacy and safety of high-dose dual therapy (HDDT) for eradicating Helicobacter pylori infection.

Aim. To evaluate the efficacy and safety of HDDT of the H. pylori eradication regimen, as well as the possible increase in the efficacy of this regimen with the addition of rebamipide.

Materials and methods. All patients with verified H. pylori infection were randomized into three groups depending on the treatment regimen. The Era-AmIPP group (n = 24) received HDDT (esomeprazole 120 mg/day and amoxicillin 3000 mg/day) for 14 days. The Era-RebAmIPP group (n = 121) received HDDT with rebamipide 300 mg/day for 14 days. The comparison group (n = 101) received conventional triple eradication therapy enhanced with bismuth tripotassium dicitrate for 14 days. The effectiveness of eradication was evaluated at 4–6 weeks after the end of therapy. Particular attention was paid to assessing the safety of therapy, the incidence of adverse events, and treatment adherence.

Results. The study included 246 patients. Low efficacy (87.5% [95% confidence interval [CI] 69.0–95.7]) of HDDT was shown. Adding rebamipide 300 mg/day to HDDT increased the eradication rate to 96.3% (95% CI 90.9–98.6). The efficacy of the Era-RebAmIPP regimen in patients previously treated with conventional eradication regimens was 91.7% (95% CI 64.6–98.5). Adverse events were reported in 37.5% (95% CI 21.2–57.3) patients in the Era-AmIPP group, 19.8% (95% CI 13.7–27.8) in the Era-RebAmIPP group, and 31.3% (95% CI 22.9–41.1) in the comparison group (p = 0.07).

Conclusion. The efficacy of the Era-RebAmIPP regimen is comparable to conventional triple therapy with bismuth. To assess the effectiveness of this regimen, larger-scale studies are required in various regions of our country.

Terapevticheskii arkhiv. 2025;97(8):642-650
pages 642-650 views

Serological markers as predictors of the severity of gastric mucosal atrophy in autoimmune and Helicobacter рylori-associated gastritis

Chebotareva M.V., Nikolskaya K.A., Andreev D.N., Dorofeev A.S., Khomeriki S.G., Tsapkova L.A., Parfenchikova E.V., Veliev A.M., Spasenov A.Y., Voynovan I.N., Bordin D.S.

Abstract

Aim. To evaluate the possibility of using serum markers of atrophy (pepsinogens – PG I and II) to form high-risk groups for gastric cancer (Operative Link for Gastritis Assessment – OLGA stage III–IV) depending on the etiology of gastritis.

Materials and methods. A total of 237 (56 men and 181 women) patients were examined. All patients underwent a 13C-urea breath test, a blood test for GastroPanel (PG I, PG II, gastrin-17, antibodies to Helicobacter pylori immunoglobulin G), a blood test for antibodies to gastric parietal cells. All patients underwent esophagogastroduodenoscopy with a biopsy of the gastric mucosa from 5 standard points according to the Sydney system and a histomorphological study according to the OLGA system, as well as a biopsy to detect H. pylori infection using the polymerase chain reaction. The patients were divided into 3 groups depending on the etiology of gastritis: Group 1 included 55 patients with chronic gastritis, autoimmune gastritis and associated with H. pylori gastritis (AIG+HP+); Group 2 – 47 patients with AIG and negative tests for H. pylori infection (AIG+HP-); Group 3 – 135 patients with chronic gastritis associated with H. pylori and negative markers of AIG (AIG-HP+).

Results. The analysis showed that in patients with AIG (group 2), the most reliable serological markers of atrophy predicted severe atrophy (OLGA stage III–IV): when the ratio PG I/PG II was ≤ 3, it was detected in 70.21% of cases, and when PG I decreased to ≤ 30 μg/L, it was found in 68.08%. In group 1, stages III–IV according to OLGA were diagnosed in 20% of cases with PG I/PG II indicators ≤ 3; and in 18.18% with a decrease in PG I ≤ 30 μg/L. When analyzing the diagnostic accuracy of GastroPanel biomarkers in identifying severe atrophy (OLGA stages III–IV) in the total sample of patients (all 3 groups), it was possible to achieve cut-off indicators as close as possible to the reference values while maintaining a relatively high sensitivity and specificity – 75.81% and 81.50% for PG I ≤ 30 μg/L and 85.48% and 64.50% for PG I/PG II ≤ 3, respectively. The optimal cut-off in the study population for the PG I indicator was < 22.5 μg/L (sensitivity – 72.58%, specificity – 88.00%), and for the PG I/PG II ratio ≤ 2 (sensitivity – 80.65%, specificity – 78.50%).

Conclusion. Serum pepsinogens can be used in the Moscow population as a non-invasive marker of gastric mucosa atrophy for the formation of high-risk patient groups for gastric cancer requiring endoscopic examination.

Terapevticheskii arkhiv. 2025;97(8):651-659
pages 651-659 views

Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors

Maev I.V., Andreev D.N., Shaburov R.I., Zaborovsky A.V., Fomenko A.K., Sokolov P.S., Tsaregorodtsev S.V., Devkota M.K., Dicheva D.T., Cheremushkin S.V., Cheremushkinа N.V., Vychkin A.V.

Abstract

Aim. To evaluate the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 versus rifaximin monotherapy in patients with small intestinal bacterial overgrowth (SIBO) associated with long-term proton pump inhibitor (PPI) use.

Materials and methods. A prospective comparative study with two parallel groups was conducted. Eligible patients were those on continuous long-term PPI therapy (> 3 months) with confirmed SIBO. SIBO was diagnosed in all patients using a lactulose Hydrogen/Methane Breath Test (HMBT). Symptom severity was assessed using the validated "7 × 7" Questionnaire, and Quality of Life (QoL) was evaluated using the SF-36 Health Status Survey. Enrolled patients were randomized into two groups based on a 7-day treatment regimen: Group 1 received rifaximin (400 mg twice daily); Group 2 received rifaximin (400 mg twice daily) plus the probiotic Saccharomyces boulardii CNCM I-745 (Enterol® drug product, Biocodex, France; 500 mg twice daily). SIBO eradication was confirmed via repeat lactulose HMBT, and symptom severity/QoL were reassessed 4 weeks after treatment completion.

Results. 108 patients were enrolled (mean age 38.7 ± 8.9 years; 65.7% female). Mean PPI treatment duration at enrollment was 4.81 months (95% confidence interval 4.15–5.46). At 4-week follow-up, repeat lactulose HMBT showed SIBO persistence in 41.5% of Group 1 (n = 22/53) versus 21.8% in Group 2 (n = 12/55; p = 0.038). Statistically significant resolution of diarrhea was observed only in Group 2 (p = 0.033). The final median "7 × 7" Questionnaire score was significantly lower in Group 2 (p = 0.0010). Both groups showed significant trends toward QoL improvement on the SF-36 survey.

Conclusion. This prospective comparative study demonstrates that combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 appears more effective than rifaximin monotherapy for SIBO eradication, symptom regression, and QoL improvement in patients with PPI-associated SIBO.

Terapevticheskii arkhiv. 2025;97(8):660-667
pages 660-667 views

Structural and functional parameters of erythrocytes as predictors of unfavorable outcome in patients with colorectal cancer

Kruchinina M.V., Osipenko M.F., Gromov A.A., Starikov A.V.

Abstract

Aim. Identification the characteristics of fatty acids (FAs) in erythrocyte membranes and in blood serum, as well as the electrical and viscoelastic parameters of erythrocytes to assess their ability to be predictors of an unfavorable outcome in patients with colorectal cancer (CRC).

Materials and methods. 112 people with an average age of 63.1 ± 9.5 years (62 men, 50 women) with CRC of stages I–IV were examined. The patients were divided into 2 groups depending on the outcome of the disease after 6 years of follow-up: group 1 – with stabilization of the disease (n = 55), group 2 (n = 57) – with an unfavorable outcome. The FA composition of erythrocyte membranes and blood serum was studied using gas chromatography/mass spectrometry, a system based on three Agilent 7000B quadrupoles (USA). The electrical and viscoelastic parameters of erythrocytes were studied using the method of dielectrophoresis.

Results. An unfavorable outcome in patients with CRC is associated with elevated levels of docosapentaenoic acid (C22:5n-3) (p = 0.0003), docosahexaenoic acid (C22:6n-3) (p = 0.001), docosathetraenoic acid (C22:4n-6) (p = 0.004), and total omega-3 polyunsaturated fatty acids (PUFA) (p = 0.0004) in erythrocyte membranes, eicosadienoic acid (C20:2 n-6) in erythrocyte membranes (p = 0.03) and blood serum (p = 0.01), and, conversely, reduced levels of ratios saturated fatty acids (SFA)/PUFA (p = 0.004), SFA / unsaturated fatty acids (USFA) (p = 0.01) and concentrations of myristic FA (C14:0) (p = 0.03) in erythrocyte membranes, as well as with a number of changes in electrical, viscoelastic parameters of red blood cells: with increased hemolysis of red blood cells at high frequencies (106 Hz – p = 0.0006 and 5 × 105 Hz – p = 0.046), increased aggregation indices at low frequencies (105 Hz – p = 0.04 and 5 × 104 Hz – p = 0.047), as well as a shift in the crossover frequency to the high frequency range (p = 0.036). In patients with stages 1–2 of CRC, omega-6 PUFAs, eicosadienoic acid C20:2n-6 (p = 0.006), docosatetraenoic acid C22:4n-6 (p = 0.012), were of the greatest importance for differentiating disease outcomes, while total content omega-3 PUFAs in erythrocyte membranes (p = 0.0129), docosahexaenoic acid C22:6 n-3 (p = 0.0169), total content (C20:5n-3+C22:6n-3) in erythrocyte membranes (p = 0.0198), docosapentaenoic acid C22:5 n-3 (p = 0.022) were slightly less important. As in the general group of patients with CRC, the degree of hemolysis at a frequency of 106 Hz was a predictor of an unfavorable outcome in people with early stages of the oncological process. ROC analysis revealed a high potential of palmitic acid in erythrocyte membranes to predict an unfavorable CRC outcome (AUC 0.786, 95% confidence interval 0.638–0.901, sensitivity 84.4%, specificity 68.2%). The diagnostic model, which included five parameters – erythrocyte levels C16:0, ratio SFA/PUFA, total USFA, total PUFA, and serum levels C20:2n-6, had an AUC of 0.663 (95% confidence interval 0.483–0.801) with the highest sensitivity of 85.2%, but not high specificity of 60.1% for predicting an unfavorable outcome in CRC.

Conclusion. Fatty acids of erythrocyte membranes, blood serum, electrical, and viscoelastic parameters of erythrocytes should be considered as promising biomarker predictors in patients with CRC that require further study.

Terapevticheskii arkhiv. 2025;97(8):668-679
pages 668-679 views

Experience in the application of ultrasound indices for assessing the activity of inflammatory bowel diseases

Mukhametova D.D., Minnemullin I.M., Akchurina O.E., Odintsova A.K., Abdulganieva D.I.

Abstract

Aim. To evaluate the diagnostic value of ultrasound (US) parameters and indices for assessing the active inflammatory bowel diseases (IBD).

Materials and methods. The study included 115 patients with IBD, 41 (36%) patients were with ulcerative colitis (UC) and 74 (64%) – with Crohn's disease (CD). Transabdominal US examination of the intestine was performed on Sonoscape S2N, with a bowel wall thickness (BWT) of 3 mm considered the norm. To assess activity in UC, the Milan Ultrasound Criteria (MUC) score was used, and in CD – International Bowel Ultrasound Segmental Activity Score (IBUS-SAS).

Results. In active UC BWT (5.91 [4.87; 6.95] mm) was greater than in remission (2.9 [2.6; 3.1] mm; p = 0.003). For active UC diagnosis BWT greater than 3 mm had sensitivity (Se) of 90.5% and specificity (Sp) of 70.6%. The MUC in exacerbation (9 [7.88; 11.8]) was higher than in remission (4.2 [3.64; 4.9]; p < 0.001). In 31 (89%) patients in exacerbation, the MUC was higher than 6.2 (Se 88.9%, Sp 87.5%), and in 34 (97%) at a threshold of 5.18 (Se 96.3%, Sp 87.5%). In active CD, BWT (4.9 [3.8; 6.6] mm) was greater than in remission (3.18 [2.6; 3.5]; p = 0.0001), with Se 87.0%, Sp 71.4%. The IBUS-SAS in active CD (46.8 [27; 71.5]) was higher than the remission (12.6 [11.2; 30.2]; p = 0.001). At a threshold of 37.5, the IBUS-SAS had Se 92.6%, Sp 61.5%, and at 45.2, Se 92.6%, Sp 87.2%.

Conclusion. US imaging is a useful and effective tool for assessing IBD activity; a threshold value of the MUC score of 5.18 and IBUS-SAS of 45.2 suggests better diagnostic value for differentiating between exacerbation and remission.

Terapevticheskii arkhiv. 2025;97(8):680-688
pages 680-688 views

Metabolic dysfunction-associated steatotic liver disease in patients with prediabetes and type 2 diabetes mellitus

Sasunova A.N., Goncharov A.A., Morozov S.V., Pilipenko V.I., Isakov V.A.

Abstract

Aim. The aim of this study was to identify the prevalence of steatosis degrees and stages of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) in connection with the presence of carbohydrate metabolism disorders, such as prediabetes and type 2 diabetes mellitus (DM).

Materials and methods. Retrospective database search (4101 records) was performed. Vibration-controlled transient liver elastography with controlled attenuation parameter module was used for the assessment of liver steatosis and fibrosis. Based on the presence of carbohydrate metabolism disorders, subjects with MASLD were allocated to one of the following groups: MASLD without prediabetes or DM (group 1), MASLD with prediabetes (group 2) and MASLD with DM (group 3).

Results. Proportion of patients with severe liver steatosis (S3) was lowest in the group 1 (61.9%), while no difference was found between groups 2 and 3 (74.3% vs 76.7%; p = 0.5). Moderate-to-severe liver fibrosis (stages F2–F4) was less widespread in the group 1 (24.1%); significant difference by this parameter was also revealed between groups 2 and 3 (34.0% vs 45.4%; p = 0.004). Proportion of patients with metabolic dysfunction-associated steatohepatitis was similar in groups 2 and 3 (33.9% vs 35.4%; p = 0.7), but was lower in the group 1 (26.7% vs 33.9% and 35.4%; p = 0.02 and p < 0.001, respectively).

Conclusion. Carbohydrate metabolism disorders are closely associated with progressive steatosis and liver fibrosis in patients with MASLD. No differences in the severity of liver steatosis was found between groups with prediabetes and T2DM, however, in T2DM, the prevalence of advanced/severe liver fibrosis was highest among all studied groups.

Terapevticheskii arkhiv. 2025;97(8):689-695
pages 689-695 views

Clinical portraits of patients with gluten-associated diseases (according to the North-West Center for the Treatment of Patients with Gluten-Associated Diseases)

Bakulin I.G., Semenova E.A., Avalueva E.B., Shostka A.G., Efremova A.Y.

Abstract

Aim. To present the interim results of the work of the specialized Register of gluten-associated disorders, created at the North-West Center for the Treatment of Gluten-Associated Disorders (NWCT GAD) on the basis of the Department of Internal Medicine Propedeutics, Gastroenterology and Dietetics n.a. S.M. Ryss, the Mechnikov North-Western State Medical University.

Materials and methods. From November 2022 to January 2024, 120 patients were examined on the basis of the NWCT GAD, of which 60 patients met the requirements of the Register and were regarded as patients with gluten intolerance or a genetic predisposition to it.

Results. The average age of patients was 35.4 ± 12 years, women predominated – 56.7%. In the structure of nosological forms of GAD, the diagnosis of “celiac disease” was more common (55%). In 23 patients, the primary diagnosis of celiac disease was revised due to the lack of criteria for the disease due to erroneous interpretation of the results and insufficient examination. Gastrointestinal symptoms were observed in 74.2%, extraintestinal manifestations – in 85.5% of patients. Among the patients included in the Register, 31 (51.7%) person had already followed a gluten-free diet for more than 3 months, but in 29 persons various clinical manifestations were observed. There was comorbidity of gluten intolerance with functional diseases of the pancreatobiliary system (41.7%) and chronic gastritis (33.3%).

Conclusion. Thus, further work of the Register allows us to obtain new data on the course and prognosis of GAD, improve the diagnostic algorithm for certain forms of gluten intolerance with the formation of an observation plan and a version of the elimination protocol, which will affect the improvement of the quality of medical care and the quality of patients’ life.

Terapevticheskii arkhiv. 2025;97(8):696-703
pages 696-703 views

The introduction into clinical practice of an algorithm for the diagnosis of liver steatosis in patients with viral pneumonia

Turankova T.A., Brazhnikov A.Y., Moroz N.G., Mudrova A.V., Varganova D.L., Pavlov C.S.

Abstract

Aim. To study the ability and significance of detecting liver steatosis during chest computed tomography (CT) in patients with viral pneumonia.

Materials and methods. A prospective cohort study included 100 patients over the age of 18 who were hospitalized with an established diagnosis of viral pneumonia. To CT detection significant liver steatosis (more than 33%), several approaches were used: liver density less than 40 HU; decrease in liver density by at least 10 HU less than the spleen; the ratio of decrease in liver density to the spleen is less than 0.9.

Results. According to CT data 2 groups were identified: 25 patients with existing liver steatosis and metabolically associated fatty liver disease, and 74 patients of the control group without signs of significant steatosis, оne patient was excluded due to alcohol abuse. There was a significant difference in the study of liver density (31.68 ± 10.67 and 54.44 ± 5.95; p < 0.001), the ratio of decrease in liver density to spleen density (0.66 ± 0.22 and 1.16 ± 0.13; p < 0.001), as well as a decrease in liver density relative to the spleen (16.30 ± 10.38 and -7.26 ± 6.10; p < 0.001). In the steatosis group, a more severe course of pneumonia was noted (p = 0.041). The incidence of deterioration according to CT was comparable in both groups: 19 (76%) and 45 (60.8%); p = 0.169, although its severity was higher in the group with steatosis (p = 0.012). Patients from the steatosis group were significantly more often prescribed biological (88.0 and 39.19%; p < 0.001) and antibacterial therapy (68.0 and 40.54%; p = 0.017).

Conclusion. The use of assessment of liver steatosis according to CT data simultaneously with the study of the underlying disease can become an important diagnostic step determining the prognosis of the course of the disease, as well as a tool for risk stratification in patients with metabolically associated fatty liver disease.

Terapevticheskii arkhiv. 2025;97(8):704-710
pages 704-710 views

Personalised treatment of patients with immune thrombotic thrombocytopenic purpura

Galstyan G.M., Klebanova E.E., Mamleeva S.Y., Avdonin P.V., Fidarova Z.T., Drokov M.Y., Parovichnikova E.N.

Abstract

Background. Treatment of immune thrombotic thrombocytopenic purpura (iTTP) includes plasma exchange (PEX) and immunosuppression (glucocorticoids and rituximab). The addition of caplacizumab to therapy has improved treatment outcomes in iTTP. However, the available therapies focus on the duration of drug administration and clinical response rather than ADAMTS13 activity.

Aim. To evaluate the efficacy of therapy for iTTP targeting ADAMTS13 activity.

Materials and methods. Treatment of patients with iTTP was started with PEX, prednisolone (1 mg/kg) and caplacizumab (10 mg/day). PEX was discontinued after an increase of platelet count > 150×109/L. Only after PEX cessation treatment with rituximab (375 mg/m2 weekly) was started. Caplacizumab was discontinued when partial remission (ADAMTS13 > 20%) was achieved. Rituximab and glucocorticoids were discontinued when complete remission (ADAMTS13 > 40%) was achieved. Platelet count, schistocyte count, haemoglobin, haptoglobin, lactate dehydrogenase activity, ADAMTS13, ADAMTS13 inhibitor titre, number of PEX, plasma volume replaced, time to increase platelet count > 150×109/L, achievement of partial and complete remission were analyzed. Data are presented as median and interquartile range.

Results. From 2021 to 2025, the diagnosis of TTP was confirmed in 102 patients. 35 patients were included in the study. Platelet counts > 150×109/L were achieved after 4 (3–5) PEX procedures in 4 (3–4.5) days. In total, 11 395 (7241–16 343) ml of plasma were exchanged. Partial remission was achieved in 100% of patients, the duration of caplacizumab therapy was 23 (12–30) days. Rituximab was administered from 4 to 8 times (median 4), complete remission was achieved in 33 out of 35 patients, 2 patients achieved only partial remission, they were treated with bortezomib and 1 with anti-CD38 monoclonal antibody. The probability of complete remission was 97.1%.

Conclusion. The duration of therapy with caplacizumab, rituximab and glucocorticoids in patients with iTTP should be determined by the achievement of target ADAMTS13 activity.

Terapevticheskii arkhiv. 2025;97(8):711-718
pages 711-718 views

Clinical notes

Side effects and ineffectiveness of standard therapy for idiopathic recurrent pericarditis: status of the problem and description of clinical cases. Case report

Petrukhina A.A., Safiullina A.А., Osmolovskaya Y.F., Zhirov I.V., Stukalova O.V., Shitov V.N., Tereshchenko S.N.

Abstract

Idiopathic recurrent pericarditis is a rare pathology characterised by recurrent inflammation in the cardiac cavity. Treatment of recurrent pericarditis is empirical and based on the use of drugs with anti-inflammatory properties. First-line drugs are non-steroidal anti-inflammatory drugs and colchicine, second-line drugs are glucocorticosteroids. This is associated with the development of undesirable side effects, which makes it impossible to continue therapy in a number of patients. This article presents two clinical cases, describes the course of the disease and the development of complications at different stages. This article demonstrates the complexity of selecting the optimal therapy in real clinical practice.

Terapevticheskii arkhiv. 2025;97(8):719-726
pages 719-726 views

Reviews

The use of plant protein-based foods for the correction of dietary patterns in alimentary-dependent diseases: opportunities and prospects. A review

Morozov S.V., Pilipenko V.I., Isakov V.A., Sasunova A.N., Goncharov A.A., Kochetkova A.A.

Abstract

Idiopathic recurrent pericarditis is a rare pathology characterised by recurrent inflammation in the cardiac cavity. Treatment of recurrent pericarditis is The possibilities of using food products based on vegetable protein to correct nutritional patterns in alimentary-dependent diseases (ADDs) of the digestive system have not been sufficiently studied. The purpose of the review is to analyze the literature data to determine the possibilities of using vegetable protein products to correct nutritional patterns in the most common ADDs of the digestive system. We searched the PubMed/MEDLINE, EMBASE, Google Scholar, CyberLeninka, and Elibrary databases with keywords corresponding to the study goals. There were 314 studies identified; however, after excluding duplicate publications and analyzing relevant data, 66 papers were included. The analysis results showed a possible benefit from using vegetable protein, which may be of clinical importance in diseases such as metabolically associated fatty liver disease, gastroesophageal reflux disease, and irritable bowel syndrome. Data on the adequacy of diets with vegetable protein and possible adverse events during their use are presented. The technological and economic prospects of using products based on vegetable proteins to correct nutritional patterns in patients with ADDs of the digestive system are addressed.

Terapevticheskii arkhiv. 2025;97(8):727-734
pages 727-734 views

Fixed-dose combinations of hypoglycemic drugs: potential of alogliptin/pioglitazone in type 2 diabetes mellitus: a review

Butranova O.I., Zyryanov S.K., Melnikova A.R., Matsepuro A.E.

Abstract

Type 2 diabetes mellitus is one of the most common chronic diseases, which is a risk factor for a wide range of complications. The introduction of an approach consisting of early administration of combination hypoglycemic therapy into clinical practice makes it relevant to study available fixed-dose combinations of hypoglycemic drugs. Alogliptin and pioglitazone are of interest in terms of their complex effect on the patient's organism. The purpose of this review is to assess the advantages of the combination of alogliptin and pioglitazone based on an analysis of published data on the pharmacodynamics, pharmacokinetics, efficacy and safety of these drugs.

Terapevticheskii arkhiv. 2025;97(8):735-749
pages 735-749 views

History of medicine

Medicine during the Great Patriotic War of 1941–1945

Pashkov K.A.

Abstract

The article highlights the main events, discoveries and principles of organizing medical care at the front and in the rear during the Great Patriotic War of 1941–1945. The main aspects of the battlefield medical doctrine, the system of stepwise casualty care, the complex of anti-epidemic measures, the care of motherhood and childhood, the role of outstanding scientists and health care organizers in the victory over fascism are considered.

Terapevticheskii arkhiv. 2025;97(8):750-758
pages 750-758 views